---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-122309"
form_type: "8-K"
ticker: "SEER"
cik: "0001726445"
company_name: "Seer, Inc."
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:40:47.890825+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Seer Q3 2024 revenue $4.0M, net loss $21.3M; FY guidance reaffirmed $13-15M

## Summary
- Q3 revenue $4.0M vs $4.2M YoY (down 3%); product revenue $3.1M, service $847K, grant $90K.
- Net loss $21.3M vs $21.1M YoY; gross margin 48%; operating expenses down 6% to $26.3M.
- Repurchased 3.7M shares at avg $1.78 in Q3; total 5.7M shares repurchased to date.
- Entered co-marketing agreement with Thermo Fisher Scientific for Proteograph suite with Orbitrap Astral mass specs.
- Cash, equivalents & investments $312M; FY 2024 revenue guidance reaffirmed at $13-15M.

## SEC filing metadata
- accession: 0000950170-24-122309
- form_type: 8-K
- ticker: SEER
- cik: 0001726445
- company_name: Seer, Inc.
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1726445/000095017024122309/0000950170-24-122309-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1726445/000095017024122309/ck0001726445-20241106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-122309
- JSON: https://secwatch.observer/filing/0000950170-24-122309.json
- Plain text: https://secwatch.observer/filing/0000950170-24-122309.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.